



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 285 432 B1**

12

EUROPEAN PATENT SPECIFICATION

- 45 Date of publication of patent specification: 11.11.92 51 Int. Cl.⁵: **C07H 19/16, C07H 19/19, A61K 31/70**
21 Application number: 88302922.5
22 Date of filing: 31.03.88

54 Therapeutic nucleosides.

- 30 Priority: 03.04.87 GB 8708050
43 Date of publication of application: 05.10.88 Bulletin 88/40
45 Publication of the grant of the patent: 11.11.92 Bulletin 92/46
54 Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE
56 References cited:
EP-A- 0 219 829
US-A- 3 658 787

JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 7, 1986 MONTGOMERY et al. "9-(2'-Deoxy-2-fluoro- -arabino-furanosyl)guanine: A Metabolically Stable Cytotoxic Analogue of 2'-Deoxyguanosine" pages 2389-2392

- 73 Proprietor: **THE WELLCOME FOUNDATION LIMITED**
Unicorn House 160 Euston Road
London NW1 2BP(GB)
72 Inventor: Tuttle, Joel Van
2306-G Lednum Street
Durham North Carolina 27705(US)
Inventor: Krenitsky, Thomas Anthony
106 Laurel Hill Road
Chapel Hill North Carolina 2751(US)
74 Representative: Garrett, Michael et al
The Wellcome Research Laboratories Group
Patents and Agreements Langley Court
Beckenham Kent BR3 3BS(GB)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to certain 2'-fluoronucleosides for use in medical therapy particularly in the treatment or prophylaxis of viral infections especially human retroviral infections.


5 AIDS is an immunosuppressive or immunodestructive disease that predisposes subjects to fatal opportunistic infections. Characteristically, AIDS is associated with a progressive depletion of T-cells, especially the helper-inducer subset bearing the OKT⁴ surface marker.

Human Immunodeficiency Virus (HIV) has been reproducibly isolated from patients with AIDS or with signs and symptoms that frequently precede AIDS. HIV is cytopathic and appears to preferentially infect and destroy OKT⁴ -bearing T-cells, and it is now generally recognized that HIV is the etiological agent of AIDS.

Since the discovery of HIV as the etiological agent of AIDS, numerous proposals have been made for anti-HIV chemotherapeutic agents that may be effective in the treatment of AIDS. Thus, for example, European Patent Specification No. 196185 describes 3'-azido-3'-deoxythymidine (which has the approved name zidovudine) and its pharmaceutically acceptable derivatives and their use in the treatment of human retrovirus infections including AIDS and associated clinical conditions.

It has now been found that certain 2'-fluoronucleosides of general formula (I) below have exceptionally potent activity against HIV which renders the compounds and their derivatives useful in the treatment of prophylaxis of AIDS and related conditions.

20 The above mentioned 2'-fluoronucleosides have the general formula



(I)

35 in which R represents hydrogen, hydroxy, C₁₋₆ alkyl, amino or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl (e.g. cyclopropylamino). The compounds of formula (I) and their pharmaceutically acceptable derivatives are hereinafter referred to as the compounds according to the invention.

According to one feature of the present invention we provide the use of a compound of general formula (I) (as defined above) or a pharmaceutically acceptable derivative in the manufacture of a medicament for the treatment or prophylaxis of a human retroviral infection.

40 The compounds of formula (I) in which R is hydroxy or amino have previously been described in the literature; for example in J.A. Montgomery et al., J. Med. Chem., 1986, 29, 2389-92, which discloses the cytotoxic evaluation of the above compounds. Other compounds of formula (I) are disclosed in European Patent Specification No. 219829.

45 The present invention further includes as new compounds the compounds of formula (I) above and their pharmaceutically acceptable derivatives in which R represents either C₁₋₆ alkyl or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl.

Particularly preferred compounds of the invention include:

- 1) 2,6-Diamino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine.
- 2) 9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine.
- 3) 2-Amino-6-(cyclopropylamino)-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine.
- 50 5) 2-Amino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine.

Compound 1) above is especially preferred on the basis of the high anti-HIV activity.

55 The present invention further provides a compound of formula (I) (in which R represents either C₁₋₆ alkyl or amino substituted by C₁₋₄ alkoxy or C₃₋₆ cycloalkyl) or a pharmaceutically acceptable derivative thereof for use in medical therapy particularly in the treatment or prophylaxis of viral infections especially human retroviral infections.

Examples of retroviral infections which may be treated or prevented in accordance with the invention

include human retroviral infections such as Human Immunodeficiency Virus (HIV), HIV-2 and Human T-cell Lymphotropic Virus (HTLV) e.g. HTLV-I or HTLV-IV infections. The compounds according to the invention are especially useful for the treatment or prophylaxis of AIDS and related clinical conditions such as AIDS-related complex (ARC), progressive generalised lymphadenopathy (PGL), AIDS-related neurological conditions, such as multiple sclerosis or tropical paraparesis, anti-HIV antibody-positive and HIV-positive conditions, Kaposi's sarcoma and thrombocytopenic purpura. The compounds may also be used in the treatment or prevention of psoriasis.

By "a pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt, ester or salt of such ester, or any other compound which upon administration to the recipient is capable of providing (directly or indirectly) the parent compound of formula (I)

Preferred esters of the compounds of formula (I) include carboxylic acid esters in which the non-carbonyl moiety of the ester grouping is selected from straight or branched chain alkyl, alkoxyalkyl (e.g. methoxymethyl), aralkyl (e.g. benzyl) aryloxyalkyl (e.g. phenoxymethyl), aryl (e.g. phenyl) optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy; sulphonate esters such as alkyl- or aralkylsulphonyl (e.g. methansulphonyl); amino acid esters (e.g. L-valyl or L-isoleucyl); and mono-, di- or triphosphate esters.

With regard to the above-described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 18 carbon atoms, particularly 1 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.

Any reference to any of the above compounds also includes a reference to a pharmaceutically acceptable salt thereof.

Examples of pharmaceutically acceptable salts of the compounds of formula (I) include base salts such as alkali metals (e.g. sodium), alkaline earth metals (e.g. magnesium), ammonium and NX₄⁺ (wherein X is C₁₋₄ alkyl) salts.

The compounds according to the invention may be employed in medical therapy in combination with other therapeutic agents, for example 3'-azido-3'-deoxy thymidine (zidovudine), acyclic nucleoside derivatives such as 9-(2-hydroxyethoxymethyl)-guanine (acyclovir), 2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine, interferons such as alpha-interferon, nucleoside transport inhibitors such as diprydamole, glucuronidation inhibitors such as probenecid, immunomodulators such as granulocyte macrophage colony stimulating factor (GM-CSF) and other agents for example as described in European Patent Specification 217580. The component compounds of such combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times e.g. sequentially such that a combined effect is achieved.

The compounds according to the invention, also referred to herein as the active ingredient, may be administered for therapy by any suitable route including oral, rectal, nasal, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous and intradermal). It will be appreciated that the preferred route will vary with the condition and age of the recipient, the nature of the infection and the chosen active ingredient.

In general a suitable dose will be in the range of 3.0 to 120 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg per kilogram body weight per day and most preferably in the range 15 to 60 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.

Experiments suggest that a dose should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 μ M, preferably about 2 to 50 μ M, most preferably about 3 to about 30 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 100 mg/kg of the active ingredient. Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

While it is possible for the active ingredient to be administered alone it is preferably to present it as a pharmaceutical formulation. The formulations of the present invention comprise at least one active ingredient, as above defined, together with one or more acceptable carriers thereof and optionally other therapeutic agents. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Those formulations in which the active ingredient is a compound of formula (I) in which R represents either C₁₋₆ alkyl or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl, or a pharmaceutically acceptable derivative thereof represent a further feature of the present invention. Formulations include those suitable for oral, rectal, nasal, topical (including

buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.

5 In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous where the base is a purine, as such compounds are susceptible to acid hydrolysis.

Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured basis, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredients in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredients such carriers as are known in the art to be appropriate.

Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the additions of the sterile carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.


Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.

The present invention further includes a process for the preparation of a compound according to the invention and pharmaceutically acceptable derivatives thereof which comprises either:

(A) reacting a compound of formula:

50

55



(II)

(wherein R is as hereinbefore defined and A represents a precursor group for the hydroxy group, or for a pharmaceutically acceptable derivative group thereof) with an agent or under conditions serving to convert the said precursor group into the corresponding desired group; or
(B) reacting a purine base of formula

B - H (III)

wherein B is the required purine moiety of a compound according to the invention).
or a functional equivalent thereof, with a compound serving to introduce the desired arabinofuranosyl ring at the 9- position of the purine base of formula (III); or

(C) for the preparation of a compound of formula (I) in which R is hydroxy, reacting the corresponding compound of formula (I) in which R is amino with an agent (e.g. adenosine deaminase) serving to convert the said amino group to a hydroxy group;

and thereafter, or simultaneously therewith, effecting one or more of the following optional conversions:-

(i) when a compound of formula (I) is formed, converting it into a pharmaceutically acceptable derivative thereof,

(ii) when a pharmaceutically acceptable derivative of a compound of formula (I) is formed, converting the said derivative into a compound of formula (I), or a different derivative thereof.

The above-described process for the preparation of a compound of formula (I) in which R represents either C₁₋₆ alkyl or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl or a pharmaceutically acceptable derivative thereof represents a further feature of the present invention.

In the above-described process according to the invention, it will be appreciated that the precursor compounds of formula (I) as well as the above-mentioned agents and conditions, will be selected from those that are known in the art of nucleoside synthetic chemistry. Examples of such conversion procedures are described hereinafter for guidance and it will be understood that they can be modified in conventional manner depending on the desired compound of formula (I). In particular, where a conversion is described which would otherwise result in the undesired reaction of labile groups then such groups may be protected in conventional manner, with subsequent removal of the protecting groups after completion of the conversion.

With regard to process (A), A may represent a protected hydroxy group e.g. an ester grouping of the type referred to above in relation to formula (I) particularly acetoxy, or an ether group such as a trialkylsilyloxy group, e.g. t-butyltrimethylsilyloxy or an aralkoxy group e.g. triphenylmethoxy. Such groups may be converted for example by hydrolysis to the desired hydroxy group or by transesterification, to an alternative ester group.

With regard to process (B), this may be effected for example by treating an appropriate purine base of formula (III) or a salt or protected derivative thereof, with a 2'-deoxy-2'-fluoroarabinose derivative for example in the presence of the appropriate pentosyl transferring enzyme.

A compound of formula (I) may be converted into a pharmaceutically acceptable phosphate or other ester by reaction with respectively a phosphorylating agent, e.g. POCl₃ or an appropriate esterifying agent, e.g. an acid halide or anhydride. The compound of formula (I), including esters thereof, may be converted into pharmaceutically acceptable salts thereof in conventional manner, e.g. by treatment with an appropriate base. An ester or salt of a compound of formula (I) may be converted into the parent compound, e.g. by hydrolysis.

The following Examples are intended for illustration only and are not intended to limit the scope of the invention in any way. The term 'active ingredient' as used in the Examples means a compound of formula

(I) or a pharmaceutically acceptable derivative thereof.

Example 1

2,6-Diamino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine

2,6-Diaminopurine (Pacific Chemical Laboratories, 1.0 g, 6.4 mmoles) and 1-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)thymine (C.H. Tann et al., J. Org. Chem. 50:3647, 1985; 0.3 g, 1.2 mmoles) was suspended in 100 ml of 5 mM potassium phosphate buffer, pH 7.0, which contained 0.04% (w/v) potassium azide. Thymidine phosphorylase (160,000 I.U.) and purine nucleoside phosphorylase (290,000 I.U.) (T.A. Krenitsky et al., Biochemistry, 20:3615, 1981 and U.S. Patent 4,381,444) absorbed onto 69 ml of DEAE-cellulose were added and the suspension shaken at 37 °C for 1 day. The suspension was then shaken at 50 °C for 1 day at which time 2.0 g of 2,6-diaminopurine was added. After shaking for 4 additional days at 50 °C, the reaction was filtered. The filter cake was washed with water and the filtrates combined and the solvent removed under vacuum. The residue was dissolved in water and applied to a 2.5 x 17 cm AG1X2-hydroxide (Bio-Rad) column. After washing the column with water, the product was eluted with methanol/water (9/1). The product was further purified by chromatography on silica gel with acetonitrile/water (9/1) as the solvent followed by chromatography on silica gel with chloroform/methanol/water (80/20/2) as the solvent. After the solvent was removed under vacuum, the residue was dissolved in water and lyophilization yielded 0.2 g of title compounds that analysed as a 1.4 hydrate.

Anal. Calcd. for C ₁₀ H ₁₃ FN ₅ O ₃ · 1.4H ₂ O				
Calcd.:	C, 38.81;	H, 5.15;	N, 27.16;	F, 6.14
Found:	C, 38.66;	H, 5.07;	N, 26.83;	F, 6.52

Structure further confirmed by ¹H-NMR

Example 2

9-(2-Deoxy-2-fluoro-β-D-arabinofuranosyl)guanine

2,6-Diamino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine (0.1 g, 0.35 mmoles) prepared as in Example 1, was dissolved in 10 ml of water. Calf intestine adenosine deaminase (10 I.U., Boehringer Mannheim) was added and the solution incubated at 37 °C for one day. The solvent was removed under vacuum. The residue was dissolved in acetonitrile/water (85/15) and chromatographed on silica gel with acetonitrile/water (85/15) as the solvent. Product containing fractions were combined and the solvent removed under vacuum. The residue was dissolved in water and lyophilization yielded 0.14 g of the title compound that analysed as a 1.1 hydrate.

Anal. Calcd. for C ₁₀ H ₁₂ FN ₅ O ₄ · 1.1H ₂ O			
Calcd.:	C, 39.37;	H, 4.69;	N, 29.96
Found:	C, 39.46;	H, 4.63;	N, 22.98

Structure further confirmed by ¹H-NMR

Example 3

2-Amino-6-(cyclopropylamino)-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine

a) 2-Amino-6-(cyclopropylamino)-9-H-purine hydrochloride

A solution of 2-amino-6-chloropurine (4.6 g, 27.5 mmole) and cyclopropylamine (12.5 g, 220 mmole 8 equiv) in MeOH (100 ml) was heated at 50 °C for 18 hours. Then 2-methoxyethanol (50 ml) was added, and the reaction was heated at 70 °C for an additional 6 hours. After cooling, a small amount of unreacted

EP 0 285 432 B1

starting material was filtered off, and the filtrate was evaporated and purified on a silica gel column eluting with CHCl_3 : 5% to 10% MeOH. The product was then recrystallised twice from MeOH and once from EtOH as a hydrochloride salt to give 1.45 g, (23%) of product; m.p. 253-257 °C,

Anal. Calcd. for $\text{C}_8\text{H}_{10}\text{N}_6 \cdot \text{HCl} \cdot 1.25\text{H}_2\text{O}$				
Calcd.:	C, 41.57;	H, 5.01;	N, 36.35;	Cl, 15.34
Found:	C, 41.55;	H, 5.01;	N, 36.28;	Cl, 15.0

b) 2-Amino-6-(cyclopropylamino)-9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-9-H-purine

1-2-deoxy-2-fluoro- β -D-2-Amino-6-(cyclopropylamino)purine hydrochloride (0.5 g, 2.2 mmoles) and 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine (C.H. Tann et al., J. Org. Chem. 50:3647, 1985; 0.5 g; 1.9 mmoles) were dissolved in 6 ml of 5 mM potassium phosphate buffer, pH 7.0 which contained 0.04% (w/v) potassium azide. The pH of the solution was adjusted to 6.8 with potassium hydroxide. Thymidine phosphorylase (16,000 I.U) and purine nucleoside phosphorylase (5,500 I.U) (T.A. Krenitsky et al., Biochemistry, 20: 3615, 1981 and U.S. Patent 4,381,444) were added and the reaction incubated at 37 °C. After 20 days the reaction was filtered. Methanol was added to the filtrate to precipitate the protein and the suspension was filtered. The title compound which was contained in the filtrate was purified by successive chromatography on AG1X2-hydroxide (Bio-Rad) with water as the solvent followed by silica gel with acetonitrile/water (95/5) as the solvent followed by silica gel with chloroform/methanol/water (85/15/1.5) as the solvent. Lyophilisation yielded 0.045 g, of the title compounds that analysed as a hydrate.

Anal. Calc. for $\text{C}_{13}\text{H}_{17}\text{FN}_6\text{O}_3 \cdot \text{H}_2\text{O}$:			
Calcd.:	C, 45.61;	H, 5.59;	N, 24.55
Found:	C, 45.80;	H, 5.54;	N, 24.43

Structure further confirmed by $^1\text{H-NMR}$

Example 4

2-Amino-9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-6-methoxy-9H-purine

2-Amino-6-methoxypurine (0.4 g, 2.4 mmoles) which may be prepared according to R.W. Balsiger and J.A. Montgomery J. Org. Chem., 20: 1573, 1960) and 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine (C.H. Tann et al., J. Org. Chem., 50:3647, 1985; 0.4 g; 1.5 mmoles) were suspended in 20 ml of 5 mM potassium phosphate buffer, pH, 7.0, which contained 0.04% (w/v) potassium azide. The pH of the suspension was adjusted to 7.0 with KOH. Thymidine phosphorylase (12,000 I.U) and purine nucleoside phosphorylase (16,600 I.U) (T.A. Krenitsky et al., Biochemistry, 20:3615, 1981 and U.S. Patent 4,381,444) were added and the suspension stirred at 37 °C. On day 3, an additional 8,000 I.U. thymidine phosphorylase and 11,100 I.U. of purine nucleoside phosphorylase were added. On day 15, the reaction was diluted to 200 ml with 5 mM potassium phosphate buffer, pH 7.0, which contained 0.05% (w/v) potassium azide. The pH of the reaction was adjusted to 7.0 with KOH and 8,000 I.U. thymidine phosphorylase and 11,100 I.U. purine nucleoside phosphorylase were added. On day 20, the pH of the reaction was adjusted to 7.2 with KOH and 8,000 I.U. thymidine phosphorylase and 11,100 I.U. purine nucleoside phosphorylase were added. On day 43, 0.2 g of 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine was added. The pH of the reaction was adjusted to 6.9 with 10 mM H_3PO_4 and 8,000 I.U. thymidine phosphorylase and 2,800 I.U. purine nucleoside phosphorylase added. On day 63, the suspension was filtered. The filtrate was evaporated. The residue was dissolved in water and 2 volumes of methanol added to precipitate the protein. The suspension was filtered and the filtrate evaporated.

The residue was dissolved in water and applied to a 2.5 x 8 cm AG1X2-hydroxide (Bio-Rad) column. After washing the column with water and methanol/water (1/1), the product was eluted with methanol/water (9/1). Product containing fractions were combined and the solvent removed under vacuum. The residue was dissolved in chloroform/methanol/water (90/10/1) and applied to a 2.5 x 55 cm silica gel column. The column was eluted with chloroform/methanol/water (90/10/1). Product containing fractions were combined

and the solvent removed under vacuum. The residue was dissolved in water and lyophilisation yielded 0.021 g of title compound that analysed as a 0.5 hydrate.

Anal. Calcd. for $C_{11}H_{14}FN_5O_4 \cdot 0.5 H_2O$			
Calcd.:	C, 42.86;	H, 4.90;	N, 22.72
Found:	C, 42.92;	H, 4.93;	N, 22.61

Structure further confirmed by 1H -NMR

Example 5

2-Amino-9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-6-ethoxy-9H-purine

2-Amino-6-ethoxypurine (0.5 g, 2.8 mmoles) which may be prepared according to R.W. Balsiger and J.A. Montgomery J. Org. Chem., 25:1573, 1960) and 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine (C.H. Tann et al., J. Org. Chem., 50:3647, 1985; 0.5 g; 1.9 mmoles) were suspended in 25 ml of 5 mM potassium phosphate buffer, pH 7.0, which contained 0.04% (w/v) potassium azide. Thymidine phosphorylase (8,000 I.U.) and purine nucleoside phosphorylase (11,100 I.U.) (T.A. Krenitsky, et al., Biochemistry, 20:3615, 1981 and U.S. Patent 4,381,444) were added and the reaction stirred at 37 °C. On day 24, 8,000 I.U. of thymidine phosphorylase and 5,500 I.U. of purine nucleoside phosphorylase were added. On day 49, the reaction was diluted to 250 ml with 5 mM potassium phosphate buffer, pH 7.0, which contained 0.04% (w/v) potassium azide. The pH of the reaction was adjusted to 7.0 with KOH and 12,000 I.U. of thymidine phosphorylase and 8,300 I.U. of purine nucleoside phosphorylase were added. On day 79, the solvent was removed under vacuum. The residue was dissolved in hot water and two volumes of acetonitrile added to precipitate the protein. After standing overnight the suspension was filtered. The filtrate was evaporated. The residue was dissolved in hot water and then allowed to cool to 25 °C. The suspension was filtered and the filtrate applied to a 2.5 x 8 cm AG1X2-hydroxide (Bio-Rad) column. After washing the column with water and methanol/water (1/1) the product was eluted with methanol water (9/1). Product containing fractions were combined and the solvent removed under vacuum. The residue was dissolved in chloroform/methanol/water (90/10/1) and applied to a 2.5 x 55cm silica gel column. The column was eluted with chloroform/methanol/water (90/10/1). Product containing fractions were combined and the solvent removed under vacuum. The residue was dissolved in water and lyophilisation, yielded 0.041 g of title compound that analysed as 0.4 hydrate.

Anal. Calcd. for $C_{12}H_{16}FN_5O_4 \cdot 0.4 H_2O$			
Calcd.:	C, 44.97;	H, 5.28;	N, 21.85
Found:	C, 44.97;	H, 5.33;	N, 21.85

Structure further confirmed by 1H -NMR.

Example 6

2-Amino-9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)-9H-purine

2-Aminopurine (Pacific Chemical Laboratories, 0.3g, 2.2 mmoles) and 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine (C.H. Tann et al., J. Org. Chem., 50:3647, 1985; 0.3 g; 1.2 mmoles) were suspended in 25 ml of 5 mM potassium phosphate buffer, pH 7.0, which contained 0.04% (w/v) potassium azide. Thymidine phosphorylase (12,000 I.U.) (T.A. Krenitsky, et al., Biochemistry, 20:3615, 1981) was added and the suspension stirred at 37 °C. On day 3, 5,500 I.U. of purine nucleoside phosphorylase (T.A. Krenitsky, et al., Biochemistry, 20:3615, 1981 and U.S. Patent 4,381,444) was added. On day 18, the reaction was diluted to 200 ml with 5 mM potassium phosphate buffer, pH 7.0, which contained 0.4% (w/v) potassium azide. On day 26, 0.4 g of 2-aminopurine, 8,000 I.U. of thymidine phosphorylase, and 2,800 I.U. of purine phosphorylase were added. On day 41, 0.2 g of 1-(2-deoxy-2-fluoro- β -D-arabinofuranosyl)thymine, 8,000 I.U. of thymidine phosphorylase and 2,800 I.U. of purine nucleoside phosphorylase were added. On day 48, the reaction was diluted to 1,000 ml with 5 mM potassium phosphate buffer, pH 7.0 which contained 0.04%

EP 0 285 432 B1

(w/v) potassium azide and 2.0 g of 2-aminopurine, 16,000 I.U. of thymidine phosphorylase and 5,500 I.U. purine nucleoside phosphorylase were added. On day 54, 1 g of 2-aminopurine, 8,000 I.U. of thymidine phosphorylase, and 2,800 I.U. of purine nucleoside phosphorylase were added. On day 68, the suspension was evaporated to near dryness. Three volumes of ethanol were added to precipitate the protein and the suspension filtered. The title compound which was contained in the filtrate was purified by chromatography on AG1X2-hydroxide (Bio-Rad) with methanol/water (9/1) as the solvent followed by chromatography on silica gel with acetonitrile/water (95/5) as the solvent. Lyophilisation yielded 0.13 g of the title compound that analysed as a 0.3 hydrate.

Anal. Calcd. for $C_{10}H_{12}FN_5O_3 \cdot 0.3 H_2O$				
Calcd.:	C, 43.73;	H, 4.62;	N, 25.50;	F, 6.92
Found:	C, 43.47;	H, 4.65;	N, 25.22;	F, 7.17

Structure further confirmed by 1H -NMR.

Example 7: Tablet Formulations

The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

	<u>mg/tablet</u>	<u>mg/tablet</u>
<u>Formulation A</u>		
(a) Active ingredient	250	150
(b) Lactose B.P.	210	126
(c) Povidone B.P.	15	9
(d) Sodium Starch Glycollate	20	12
(e) Magnesium Stearate	<u>5</u>	<u>3</u>
	500	300

	<u>mg/tablet</u>	<u>mg/tablet</u>
<u>Formulation B</u>		
(a) Active ingredient	250	150
(b) Lactose	150	90
(c) Avicel PH 101	60	36
(d) Povidone B.P.	15	9
(e) Sodium Starch Glycollate	20	12
(f) Magnesium Stearate	<u>5</u>	<u>3</u>
	500	300

	<u>mg/tablet</u>
<u>Formulation C.</u>	
Active ingredient	100
Lactose	200
Starch	50
Povidone	5
Magnesium stearate	<u>4</u>
	359

The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type.

Formulation D**mg/tablet**

5

Active ingredient 250

Pregelatinised Starch NF15 148

10

Magnesium Stearate 2

400

Formulation E

15

mg/tablet

Active ingredient 250

20

Lactose 150

Avicel 98

Magnesium Stearate 2

25

500

Formulation F (Controlled Release Formulation)

30 The formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression.

35

mg/tablet

(a) Active ingredient 500

(b) Hydroxypropylmethylcellulose 112

40

(Methocel K4M Premium)

(c) Lactose B.P. 53

(d) Povidone B.P. 28

45

(e) Magnesium Stearate 7

700

Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.

50

Example 8: Capsule Formulations**Formulation A**

55

A capsule formulation is prepared by admixing the ingredients of Formulation D in Example 1 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.

Formulation Bmg/capsule

(a) Active ingredient	250
(b) Lactose B.P.	143
(c) Sodium Starch Glycollate	25
(d) Magnesium Stearate	<u>2</u>
	420

Formulation Cmg/capsule

(a) Active ingredient	250
(b) Macrogol 4000 B.P.	<u>350</u>
	600

Capsules of formulation C are prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

Formulation Dmg/capsule

Active ingredient	250
Lecithin	100
Arachis Oil	<u>100</u>
	450

Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b and c using an extruder, followed by spheronisation of the extrude and drying. The dried pellets are then coated with release- controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

		<u>mg/capsule</u>
5	(a) Active ingredient	250
	(b) Microcrystalline Cellulose	125
	(c) Lactose B.P.	125
10	(d) Ethyl Cellulose	<u>13</u>
		513

15 Example 9: Injectable Formulation

Formulation A.

20	Active ingredient	0.200g
	Hydrochloric acid solution, 0.1M q.s. to	pH 4.0 to 7.0
	Sodium hydroxide solution, 0.1M q.s. to	pH 4.0 to 7.0
25	Sterile water q.s. to	10ml

30 The active ingredient is dissolved in most of the water (35°-40° C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10ml amber glass vial (type 1) and sealed with sterile closures and overseals.

35 Formulation B.

	Active ingredient	0.125 g
40	Sterile, pyrogen-free, pH 7 phosphate buffer, q.s. to	25 ml

45 Example 10: Intramuscular injection

		<u>Weight(g)</u>
50	Active ingredient	0.20 g
	Benzyl Alcohol	0.10 g
	Glycofurol 75	1.45 g
55	Water for Injection q.s. to	3.00 ml

EP 0 285 432 B1

The active ingredient is dissolved in the glycofurool. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).

5 Example 11: Syrup

	<u>Weight(g)</u>
10 Active ingredient	0.25 g
Sorbitol Solution	1.50 g
Glycerol	2.00 g
Sodium Benzoate	0.005 g
15 Flavour, Peach 17.42.3169	0.0125 ml
Purified Water q.s. to	5.00 ml

20 The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbitol solution and finally the flavour. The volume is made up with purified water and mixed well.

When the active ingredient is poorly soluble, the following formulation (B) is used.

25

Formulation B.

	<u>Weight(g)</u>
30 Active ingredient	0.25 g
Sorbitol Solution	1.50 g
Glycerol	0.75 g
35 Dispersible Cellulose	0.1 g
Sodium Benzoate	0.005 g
Flavour	q.s.
40 Purified Water to	5.000 ml

The sorbitol solution is mixed with the glycerol and part of the purified water. The sodium benzoate is dissolved in purified water and added to the bulk. The dispersible cellulose and flavour is added and dispersed. The active ingredient is then added and dispersed and volume is made up with purified water.

45

Example 12: Suppository

50

55

mg/suppository

Active ingredient (63 μ m)*	250
Hard Fat, BP (Witepsol H15 - Dynamit NoBel)	<u>1770</u>
	2020

*The active ingredient is used as a powder wherein at least 90% of the particles are of 63 μ m diameter or less.

One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200 μ m sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250 μ m stainless steel screen and, with continuous stirring, is allowed to cool to 40°C. At a temperature of 38°C to 40°C, 2.02g of the mixture is filled into suitable, 2 ml plastic moulds. The suppositories are allowed to cool to room temperature.

Example 13: Pessariesmg/pessary

Active ingredient (63 μ m)	250
Anhydrous Dextrose	380
Potato Starch	363
Magnesium Stearate	<u>7</u>
	1000

The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.


Cell toxicity is assessed in a cell growth inhibition assay. Subconfluent cultures of Vero cells grown on 96-well microtiter dishes are exposed to different dilutions of drug, and cell viability determined daily on replicate cultures using uptake of a tetrazolium dye (MTT). The concentration required for a 50% inhibition of cell viability at 96 hours is termed CCID₅₀. The CCID₅₀ for 9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl) guanine was 39 μ M.

Antiviral Activity

9-(2-deoxy-2-fluoro- β -D-arabinofuranosyl) guanine was tested for activity against HIV in vitro in accordance with the method described by H. Mitsuya et al, Proc. Natl. Acad. Sci., USA, Vol 82, pp 7096-7100, October 1985, and found to have activity at a concentration of 1 μ M.

Claims


1. A compound of general formula (I)B



(I)B

in which R represents either C₁₋₆ alkyl, or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl or a pharmaceutically acceptable derivative thereof.


2. Use of a compound of general formula (I)A



(I)A

in which R represents hydrogen, hydroxy, C₁₋₆ alkyl, amino or amino substituted by C₁₋₆ alkoxy or C₃₋₆ cycloalkyl or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the treatment or prophylaxis of a human retroviral infection.

3. Use as claimed in claim 2 in which the compound of formula (I)A is 2,6-diamino-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purine.
4. Use as claimed in claim 2 in which the compound of formula (I)A is 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)guanine.
5. Use as claimed in any of claims 2 to 4 in which the said human retroviral infection is a Human Immunodeficiency Virus (HIV) infection.
6. Use as claimed in claim 5 in the manufacture of a medicament for the treatment or prophylaxis of Acquired Immune Deficiency Syndrome (AIDS).
7. A process for the preparation of a compound of formula (I)B according to claim (1) comprising:
 - (A) reacting a compound of formula:



(wherein R is as defined in claim 1 and A represents a precursor group for the hydroxy group, or for a pharmaceutically acceptable derivative group thereof) with an agent or under conditions serving to convert the said precursor group into the corresponding desired group; or
(B) reacting a purine base of formula

20

B - H (III)

wherein B is the required purine moiety of a compound of formula (I)B according to claim 1 or a functional equivalent thereof, with a compound serving to introduce the desired arabinofuranosyl ring at the 9- position of the purine base of formula (III);
and thereafter, or simultaneously therewith, effecting one or more of the following optional conversions:-

25

- (i) when a compound of formula (I)B is formed, converting it into a pharmaceutically acceptable derivative thereof,
 - (ii) when a pharmaceutically acceptable derivative of a compound of formula (I)B is formed, converting the said derivative into a compound of formula (I)B, or a different derivative thereof.
- 30

8. A pharmaceutical formulation comprising as active ingredient a compound of formula (I)B according to claim 1 or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable carrier therefor.

35

9. A compound of formula (I)B according to claim 1 or a pharmaceutically acceptable derivative thereof for use in medical therapy.

10. A compound as claimed in claim 9 for the treatment or prophylaxis of a human retroviral infection.

40

11. A compound as claimed in claim 9 for the treatment or prophylaxis of a Human Immunodeficiency Virus (HIV) infection.

12. A compound as claimed in claim 9 for the treatment or prophylaxis of Acquired Immunodeficiency Syndrome (AIDS).


45

Patentansprüche

1. Verbindung der allgemeinen Formel (I)B

50


55



(I)B

in der R entweder eine C₁₋₆-Alkylgruppe oder eine durch eine C₁₋₆- Alkoxy- oder C₃₋₆-Cycloalkylgruppe substituierte Aminogruppe darstellt, oder ein pharmazeutisch verträgliches Derivat davon.


2. Verwendung einer Verbindung der allgemeinen Formel (I)A



(I)A

in der R Wasserstoff, die Hydroxygruppe, eine C₁₋₆-Alkylgruppe, eine Aminogruppe oder eine durch eine C₁₋₆-Alkoxy- oder C₃₋₆-Cycloalkylgruppe substituierte Aminogruppe darstellt, oder eines pharmazeutisch verträglichen Derivates davon zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe einer retroviralen Infektion beim Mensch.

3. Verwendung gemäß Anspruch 2, wobei die Verbindung der Formel (I)A 2,6-Diamino-9-(2'-desoxy-2'-fluor-beta-D-arabinofuranosyl)-9H-purin ist.
4. Verwendung gemäß Anspruch 2, wobei die Verbindung der Formel (I)A 9-(2'-Desoxy-2'-fluor-beta- D-arabinofuranosyl)guanin ist.
5. Verwendung gemäß jedem der Ansprüche 2 bis 4, wobei die genannte retrovirale Infektion beim Mensch eine Human-Immunschwäche-Virus (HIV) - Infektion ist.
6. Verwendung gemäß Anspruch 5 bei der Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Acquired Immune Deficiency Syndrome (AIDS).
7. Verfahren zur Herstellung einer Verbindung der Formel (I)B gemäß Anspruch 1, wobei man:
 - (A) eine Verbindung der Formel:



(worin R wie in Anspruch 1 definiert ist und A eine Vorstufengruppe für die Hydroxygruppe oder für eine pharmazeutisch verträgliche Derivatgruppe davon darstellt) mit einem Mittel oder unter Bedingungen reagieren läßt, welche dazu dienen, die genannte Vorstufengruppe in die entsprechend gewünschte Gruppe zu überführen; oder wobei man

(B) eine Purinbase der Formel:

B - H (III)


worin B der erforderliche Purinrest einer Verbindung der Formel (I)B gemäß Anspruch 1 idst, oder ein funktionelles Äquivalent davon, mit einer Verbindung zur Reaktion bringt, die dazu dient, den gewünschten Arabinofuranosylring in die 9-Position der Purinbase der Formel (III) einzuführen; und wobei man danach, oder gleichzeitig damit, eine oder mehrere der folgenden gegebenenfalls vorgesehenen Umwandlungsreaktionen durchführt:

- (i) wenn eine Verbindung der Formel (I)B gebildet ist, überführt man sie in ein pharmazeutisch verträgliches Derivat davon,
- (ii) wenn ein pharmazeutisch verträgliches Derivat einer Verbindung der Formel (I)B gebildet ist, überführt man das genannte Derivat in eine Verbindung der Formel (I)B oder ein anderes Derivat davon.

8. Pharmazeutische Formulierung, enthaltend als Wirkstoff eine Verbindung der Formel (I)B gemäß Anspruch 1 oder ein pharmazeutisch verträgliches Derivat davon, zusammen mit einem pharmazeutisch verträglichen Träger dafür.
9. Verbindung der Formel (I)B gemäß Anspruch 1 oder eines pharmazeutisch verträglichen Derivats davon zur Verwendung in der medizinischen Therapie.
10. Verbindung gemäß Anspruch 9 zur Behandlung oder Prophylaxe einer retroviralen Infektion beim Menschen.
11. Verbindung gemäß Anspruch 9 zur Behandlung oder Prophylaxe einer Human-Immunschwäche-Virus (HIV)-Infektion.
12. Verbindung gemäß Anspruch 9 zur Behandlung oder Propylaxe von Acquired Immunodeficiency Syndrome (AIDS).

Revendications


1. Composé de formule générale (I)B :



(I) B

où R représente soit C₁₋₆-alcoyle, soit amino substitué par C₁₋₆-alcoxy ou C₁₋₆-cycloalcoyle, ou un dérivé pharmaceutiquement acceptable de celui-ci.


2. Utilisation d'un composé de formule générale (I)A :



(I) A

où R représente hydrogène, hydroxyle, C₁₋₆-alcoyle, amino ou amino substitué par C₁₋₆-alcoxy ou C₃₋₆-cycloalcoyle, ou d'un dérivé pharmaceutiquement acceptable de celui-ci dans la fabrication d'un médicament pour le traitement ou la prophylaxie d'infection rétrovirale humaine.

3. Utilisation suivant la revendication 2, dans laquelle le composé de formule (I)A est la 2,6-diamino-9-(2-désoxy-2-fluoro-β-D-arabinofurannosyl)-9H-purine.
4. Utilisation suivant la revendication 2, dans laquelle le composé de formule (I)A est la 9-(2-désoxy-2-fluoro-β-D-arabinofurannosyl)guanine.
5. Utilisation suivant l'une quelconque des revendications 2 à 4, dans laquelle l'infection rétrovirale humaine est une infection par le virus de l'immunodéficience humaine (VIH).
6. Utilisation suivant la revendication 5, dans la fabrication d'un médicament pour le traitement ou la prophylaxie du syndrome d'immunodéficience acquise (SIDA).
7. Procédé de préparation d'un composé de formule (I)B suivant la revendication 1, qui comprend :
(A) la réaction d'un composé de formule :



(II)

(où R est tel que défini dans la revendication 1 et A représente un radical précurseur pour le radical hydroxyle ou pour un radical dérivé pharmaceutiquement acceptable de celui-ci) avec un agent ou dans des conditions servant à convertir ce radical précurseur en le radical souhaité correspondant, ou
(B) la réaction d'une base purique de formule :

B - H (III)

(où a est la partie purine requise d'un composé de formule (I)B suivant la revendication 1) ou d'un équivalent fonctionnel de celle-ci avec un composé servant à introduire le cycle arabinofurannosyle souhaité à la position 9 de la base purique de la formule (III),

et ensuite ou simultanément, l'exécution d'une ou plusieurs des conversions facultatives suivantes :

- (i) lorsqu'un composé de formule (I)B est formé, sa conversion en un dérivé pharmaceutiquement acceptable de celui-ci,
- (ii) lorsqu'un dérivé pharmaceutiquement acceptable d'un composé de formule (I)B est formé, la conversion de ce dérivé en un composé de formule (I)B ou en un dérivé différent de celui-ci.

8. Composition pharmaceutique comprenant comme constituant actif un composé de formule (I)B suivant la revendication 1 ou un dérivé pharmaceutiquement acceptable de celui-ci, conjointement avec un excipient pharmaceutiquement acceptable.
9. Composé de formule (I)B suivant la revendication 1, ou dérivé pharmaceutiquement acceptable de celui-ci à utiliser en thérapeutique médicale.
10. Composé suivant la revendication 9, pour le traitement ou la prophylaxie d'une infection rétrovirale humaine.
11. Composé suivant la revendication 9, pour le traitement ou la prophylaxie d'une infection par le virus de l'immunodéficience humaine (VIH).
12. Composé suivant la revendication 9, pour le traitement ou la prophylaxie du syndrome d'immunodéficience acquise (SIDA).